New England Private Wealth Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-11,496
Closed -$294K 145
2024
Q3
$294K Hold
11,496
0.05% 122
2024
Q2
$270K Sell
11,496
-81
-0.7% -$2.04K 0.05% 121
2024
Q1
$328K Hold
11,577
0.06% 112
2023
Q4
$380K Buy
11,577
+81
+0.7% +$2.2K 0.07% 101
2023
Q3
$320K Hold
11,496
0.07% 94
2023
Q2
$392K Hold
11,496
0.08% 83
2023
Q1
$346K Hold
11,496
0.07% 90
2022
Q4
$325K Sell
11,496
-112
-1% -$3.56K 0.07% 86
2022
Q3
$382K Sell
11,608
-231
-2% -$8.48K 0.09% 74
2022
Q2
$545K Hold
11,839
0.1% 75
2022
Q1
$545K Buy
11,839
+72
+0.6% +$3.43K 0.1% 75
2021
Q4
$720K Buy
11,767
+11
+0.1% +$760 0.13% 64
2021
Q3
$878K Sell
11,756
-11
-0.1% -$923 0.16% 59
2021
Q2
$1.09M Buy
11,767
+112
+1% +$9.52K 0.21% 57
2021
Q1
$1.03M Buy
11,655
+342
+3% +$33.9K 0.18% 58
2020
Q4
$1.05M Buy
11,313
+7
+0.1% +$558 0.23% 53
2020
Q3
$720K Hold
11,306
0.18% 55
2020
Q2
$601K Buy
+11,306
New +$485K 0.16% 55

Other funds holding ARKG

New England Private Wealth Advisors's ARKG Position: Q4 2024 in Review

New England Private Wealth Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2024, closing a stake of 11,496 shares — an estimated $294K sold.

New England Private Wealth Advisors first reported a position in ARKG in Q2 2020 and held it in 18 quarters. The position peaked at $1.09M in Q2 2021. 238 funds tracked by Wall St. Rank hold ARKG as of Q4 2024.

  • New England Private Wealth Advisors reported no remaining ARK Genomic Revolution ETF position as of Q4 2024 after selling out during the quarter.
  • New England Private Wealth Advisors sold 11,496 ARK Genomic Revolution ETF shares in Q4 2024, an estimated $294K.
  • New England Private Wealth Advisors first reported a position in ARK Genomic Revolution ETF in Q2 2020 and held it in 18 quarters.
  • New England Private Wealth Advisors's ARK Genomic Revolution ETF position peaked at $1.09M in Q2 2021.
  • 238 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2024.

Based on New England Private Wealth Advisors's 13F filing for Q4 2024, filed 7 Feb 2025.